Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Design and development of adjuvant-active nonionic block copolymers

M J Newman1, C W Todd, M Balusubramanian

  • 1Vaxcel, Inc., 154 Technology Parkway, Norcross, Georgia 30092 and CytRx Corporation, 154 Technology Parkway, Norcross, Georgia 30092, USA. newmanm@cytrx.com

Journal of Pharmaceutical Sciences
|November 13, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Risk factors for surgical site infections in abdominal surgeries in Ghana: emphasis on the impact of operating rooms door openings.

Epidemiology and infection·2020
Same author

Surveillance of surgical site infection in a teaching hospital in Ghana: a prospective cohort study.

The Journal of hospital infection·2020
Same author

Multi-centre point-prevalence survey of hospital-acquired infections in Ghana.

The Journal of hospital infection·2018
Same author

The use of daily electronic prompts to help improve antimicrobial stewardship in a critical care unit.

Journal of infection prevention·2017
Same author

Probing the degradation and homogeneity of embedded perovskite semiconducting layers in photovoltaic devices by Raman spectroscopy.

Physical chemistry chemical physics : PCCP·2017
Same author

Prevalence and antimicrobial resistance of Salmonella serovars isolated from poultry in Ghana.

Epidemiology and infection·2016

Novel nonionic block copolymers act as effective vaccine adjuvants. Tailoring poly(oxyethylene) content customizes immune responses, enhancing vaccine efficacy for specific pathogen types.

Area of Science:

  • Polymer Chemistry
  • Immunology
  • Vaccine Development

Background:

  • Nonionic block copolymers, synthesized from propylene oxide and ethylene oxide, possess unique vaccine adjuvant properties.
  • These copolymers can be engineered with specific molecular weights and poly(oxyethylene) (POE) content to modulate their self-assembly and immune-stimulating capabilities.

Purpose of the Study:

  • To design and produce nonionic block copolymers with tailored adjuvant properties.
  • To investigate the influence of copolymer size and POE content on self-assembly into microparticles and subsequent vaccine adjuvant activity.
  • To determine how varying POE content affects the type of immune response (Type 1 vs. Type 2 helper T-lymphocyte responses).

Main Methods:

  • Synthesis of nonionic block copolymers with high molecular weight poly(oxypropylene) (POP) cores and varying POE end blocks.

Related Experiment Videos

  • Characterization of copolymer self-assembly into micelles and microparticles in aqueous solutions.
  • Formulation of protein-adjuvant complexes and evaluation of adjuvant activity.
  • Assessment of immune responses, specifically Type 1 and Type 2 helper T-lymphocyte responses, mediated by different copolymer formulations.

    • Main Results:

    • Nonionic block copolymers with <10% POE spontaneously form 300 nm-3 µm microparticles in aqueous solutions.
    • Maximal adjuvant activity was observed with low POE content (5-10%) and molecular sizes of 11-12 kDa.
    • Copolymers with 10% POE preferentially augmented Type 2 helper T-lymphocyte responses.
    • Copolymers with lower POE content (<10%) augmented both Type 1 and Type 2 helper T-lymphocyte responses.

    Conclusions:

    • Nonionic block copolymers serve as effective, customizable vaccine adjuvants.
    • The poly(oxyethylene) content is a critical factor in determining both the magnitude and type of immune response elicited.
    • These findings enable the development of vaccines with precisely tailored immune-stimulating profiles for optimal efficacy against specific pathogens.